Meta Expands AI Training With Employee Activity Tracking Tools 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
REDWOOD CITY, Calif., March 07, 2016 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it will present at the Barclays Global Healthcare Conference on Wednesday, March 16 at 2:05 pm ET in Miami Beach, Florida.
A webcast of the presentation will be available on the Investors page of the Coherus website at http://investors.coherus.com.
About Coherus BioSciences, Inc.
Coherus is a pure-play biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products, including CHS-5217 (bevacizumab biosimilar) and CHS-3351 (ranibizumab biosimilar). For additional information, please visit www.coherus.com.
CONTACT: Keith Vendola, M.D. Investor Relations Coherus BioSciences, Inc. [email protected] +1 (650) 437-6239
